EI
NXTC icon

EAM Investors’s NextCure NXTC Stock Holding History

EAM Investors’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,624
Closed -$722K – 301
2020
Q1 		$722K Sell
1,624
-1,068
-40% -$570K 0.22% 178
2019
Q4 		$1.82M Sell
2,692
-729
-21% -$366K 0.4% 93
2019
Q3 		$1.27M Buy
+3,421
New +$1.11M 0.34% 147

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Investors's NXTC Position: Q2 2020 in Review

EAM Investors sold out of NextCure (NXTC) in Q2 2020, closing a stake of 1,624 shares — an estimated $722K sold.

EAM Investors first reported a position in NXTC in Q3 2019 and held it in 3 quarters. The position peaked at $1.82M in Q4 2019. 88 funds tracked by Wall St. Rank hold NXTC as of Q2 2020.

  • EAM Investors reported no remaining NextCure position as of Q2 2020 after selling out during the quarter.
  • EAM Investors sold 1,624 NextCure shares in Q2 2020, an estimated $722K.
  • EAM Investors first reported a position in NextCure in Q3 2019 and held it in 3 quarters.
  • EAM Investors's NextCure position peaked at $1.82M in Q4 2019.
  • 88 funds tracked by Wall St. Rank held NextCure as of Q2 2020.

Based on EAM Investors's 13F filing for Q2 2020, filed 13 Aug 2020.